Diagenode

Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization


Schanda J. et al.

RUNX1/ETO, the product of the t(8;21) chromosomal translocation, is required for the onset and maintenance of one of the most common forms of acute myeloid leukemia (AML). RUNX1/ETO has a modular structure and, besides the DN A-binding domain (Runt), contains four evolutionary conserved functional domains named nervy homology regions 1-4 (NHR1 to N HR4). The NHR domains serve as docking sites for a variety of different proteins and in addition the N HR2 domain mediates tetramerization through hydrophobic and ionic /polar interactions . Tetramerization is essential for RUNX1/ETO oncogenic activity. Destabilization of the RUNX1/ETO high molecular weight complex abrogates RUNX1/ETO oncogenic activity. Using a structure-based virtual screening, we identified several small molecule inhibitors mimicking the tetramerization hot spot within the NHR2 domain of RUNX1/ETO. One of these compounds, 7.44, was of particular interest as it showed biological activity in vitro and in vivo.

Tags
Antibody

Share this article

Published
February, 2017

Source

Products used in this publication

  • ChIP kit icon
    C01010055
    iDeal ChIP-seq kit for Transcription Factors
  • Antibody ChIP-seq grade icon
    C15310197
    AML1-ETO polyclonal antibody - Classic
  • RFX5-polyclonal-antibody-diagenode
    C15410206
    Rabbit IgG

         Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics